Yellow Jersey Therapeutics and atopic dermatitis antibody NM26 acquired by Johnson & Johnson
Johnson & Johnson has entered into an agreement with the biotech company Numab Therapeutics to acquire the subsidiary Yellow Jersey Therapeutics and the bispecific antibody NM26, which is being tested against two types of atopic dermatitis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.